"Greater scientific collaboration is critical in reviving economic growth and scalable recovery as we battle this COVID-19 pandemic. Before COVID-19, the global biotech industry was estimated to expand at 9.9% CAGR to reach $775 billion by 2024. Asia Pacific holds the second largest share of biotech firms globally (24%), second only to the U.S. which makes up 48.2%.
More importantly, this pandemic has shown us that in addition to our ongoing work, there are many unmet patient health needs, which must be addressed urgently.
Realistically, we will only be able to achieve such goals in a reasonable timeframe by improving the way that we pool together our resources."